Rigosertib
From WikiMD's WELLNESSPEDIA
| Chemical Compound | |
|---|---|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider ID | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Properties | |
| Chemical Formula | |
| Molar Mass | |
| Appearance | |
| Density | |
| Melting Point | |
| Boiling Point | |
| Hazards | |
| GHS Pictograms | [[File:|50px]] |
| GHS Signal Word | |
| GHS Hazard Statements | |
| NFPA 704 | [[File:|50px]] |
| References | |
Rigosertib (ON-01910 sodium salt, with Estybon as trade name) is a synthetic benzyl styryl sulfone in development by Onconova Therapeutics.[1] Riosertib is in phase III clinical trials for the treatment of chronic myelomonocytic leukemia.[2]
Its geometrical isomer (Z)-ON 01910·Na has less cytotoxicity on cancer cells.
Mechanism[edit]
Rigosertib is a microtubule-destabilizing agent.[3]
References[edit]
- ↑ Onconova Therapeutics(link). {{{website}}}. Accessed 2019-04-26.
- ↑ https://clinicaltrials.gov/ct2/show/NCT01928537
- ↑ "Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent".Molecular Cell.2017;68(1)
- 210–223.e6.doi:10.1016/j.molcel.2017.09.012.PMID:28985505.PMC:5640507.Full text.
 | This medical article is a stub. You can help WikiMD by expanding the page. |
